Eli Lilly's LillyDirect sales channel, which has become an important driver of sales of its weight-loss therapies in the US, ...

The company is seeking to expand its resources for patients on GLP-1s, including tracking medication and biometrics with Ōura ...

This partnership marks another addition to the growing list of high-profile collaborations between the consumer health and ...

He added that the company's plan to sell Foundayo through government channels will depend on the pricing implications of the ...

Eli Lilly will launch its obesity pill in Europe through direct sales before seeking public healthcare reimbursement.

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...

May 8 (Reuters) - Eli Lilly's ⁠new ⁠weight-loss pill, Foundayo, was ⁠prescribed 7,335 times in the U.S. in the fourth week, a modest uptake compared to rival Novo Nordisk's Wegovy pill, analysts ‌said ...

Amazon (NASDAQ: AMZN) just made a quiet move that could reshape how Americans access weight-loss drugs. On April 9, 2026, it announced that its pharmacy unit will stock new GLP-1 weight-loss pill ...